Creatine Therapy for Huntington's Disease
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00026988 |
Recruitment Status
:
Completed
First Posted
: November 16, 2001
Last Update Posted
: August 18, 2006
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Huntington's Disease | Drug: Creatine | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 64 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | Creatine Therapy for Huntington's Disease |
Study Start Date : | October 2001 |
Study Completion Date : | June 2006 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
- Diagnosis of HD confirmed by known family history or by CAG repeat expansion >37.
- Clinical stage I or II as determined by a functional capacity scale >7; must have evident motor signs
- Men and women >18 years if age with a clinical diagnosis of HD. Women of childbearing age may participate if they have a negative pregnancy test at screening and are either using adequate birth control, post menopausal, or are surgically sterile.
- Stable doses of any psychotropic medications for 4 weeks prior to randomization and should be maintained on constant dosage throughout the course of the trial.
- Capable of providing informed consent

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00026988
United States, Massachusetts | |
Steven Hersch, M.D., Ph.D. | |
Boston, Massachusetts, United States, 02129 | |
United States, New York | |
Andrew Feigin, M.D. | |
Long Island, New York, United States | |
Karen Marder, M.D. | |
New York, New York, United States, 10032 | |
Peter Como, Ph.D. | |
Rochester, New York, United States, 14642 |
Principal Investigator: | Steven Hersch, MD | Harvard School of Medicine |
ClinicalTrials.gov Identifier: | NCT00026988 History of Changes |
Other Study ID Numbers: |
R01AT000613-01 ( U.S. NIH Grant/Contract ) |
First Posted: | November 16, 2001 Key Record Dates |
Last Update Posted: | August 18, 2006 |
Last Verified: | July 2006 |
Keywords provided by National Center for Complementary and Integrative Health (NCCIH):
Huntington's disease creatine energy depletion |
Additional relevant MeSH terms:
Huntington Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Dementia Chorea Dyskinesias |
Movement Disorders Heredodegenerative Disorders, Nervous System Neurodegenerative Diseases Genetic Diseases, Inborn Cognition Disorders Neurocognitive Disorders Mental Disorders |